NCT03476473|Unknown
Loading search results
Sponsor study identifier
observational
200
1 country
1
Study Start
February 16, 2018
Actual (reported)Primary Completion
March 26, 2018
Actual (reported)Study Completion
December 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This study aims to evaluate the presence of lung function impairment in a sample of patients diagnosed with non-affective psychosis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 16, 2018
Actual (reported)March 19, 2018
Actual (reported)March 26, 2018
Actual (reported)March 26, 2018
Actual (reported)December 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The incidence of COPD and asthma diagnosed by spirometry.
The spirometer variables will be forced vital capacity (FVC) (i.e. the maximal volume of air, in litres, that can be forcefully expelled from the lungs after maximal inhalation) and forced expiratory volume in 1 s (FEV1) (i.e. the volume of air that can be forcefully expelled from the lungs in the first second after maximal inhalation, in litres). From a minimum of two technically acceptable and consistent efforts, the highest readings of FEV1 and FVC will be recorded and used in the analyses. Spanish reference values will be used to compute the individual FEV1 and FVC values as a percentage of those predicted for corresponding age, gender and height in healthy, non-smoking adults. Based on spirometry results, pulmonary obstruction is defined as a FEV1/FVC \<70%; and restriction as a FVC \<80% of the predicted value and a FEV1/FVC \>70% to exclude obstruction.
10 years
Individuals included in the Longitudinal Long-term Study of First Episode Psychosis Clinical Program (10 PAFIP) at the University Hospital Marqués de Valdecilla (Santander - Cantabria).
University Hospital Marqués de Valdecilla
Santander, Cantabria, 39008, Spain
Mayoral-van Son J, Juncal-Ruiz M, Ortiz-Garcia de la Foz V, Vazquez-Bourgon J, Setien-Suero E, Tordesillas-Gutierrez D, Gomez-Revuelta M, Ayesa-Arriola R, Crespo-Facorro B; PAFIP Research Group. Long-term clinical and functional outcome after antipsychotic discontinuation in early phases of non-affective psychosis: Results from the PAFIP-10 cohort. Schizophr Res. 2021 Jun;232:28-30. doi: 10.1016/j.schres.2021.04.011. Epub 2021 May 16. No abstract available.
Ana Viejo Casas
Instituto de Investigación Marqués de Valdecilla
First Submitted
March 19, 2018
First Posted
March 26, 2018
Study Start
February 16, 2018
Actual (reported)Primary Completion
March 26, 2018
Actual (reported)Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Contact the study team to confirm eligibility.
Study Completion
December 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 16, 2020
Record last verified: 2020-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: